Terms: = Ovarian cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Prognosis
295 results:
1. Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.
Kong D; Wu Y; Liu Q; Huang C; Wang T; Huang Z; Gao Y; Li Y; Guo H
Eur J Med Res; 2024 Apr; 29(1):231. PubMed ID: 38609993
[TBL] [Abstract] [Full Text] [Related]
2. Frizzled class receptor 5 contributes to ovarian cancer chemoresistance through aldehyde dehydrogenase 1A1.
Xia Y; Wang S; Sun Y; Wang W; Chang S; Zhang Z; Zhao C
Cell Commun Signal; 2024 Mar; 22(1):194. PubMed ID: 38539211
[TBL] [Abstract] [Full Text] [Related]
3. Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate cancer.
Kalampokis N; Zabaftis C; Spinos T; Karavitakis M; Leotsakos I; Katafigiotis I; van der Poel H; Grivas N; Mitropoulos D
Curr Oncol; 2024 Feb; 31(3):1162-1169. PubMed ID: 38534919
[TBL] [Abstract] [Full Text] [Related]
4. The analysis of preoperative or intraoperative factors in predicting the escalation of surgical pathological staging of patients with clinical stage I endometrioid carcinoma: A retrospective clinical study.
Li N; Chen Q; Li B
Medicine (Baltimore); 2024 Mar; 103(11):e37465. PubMed ID: 38489719
[TBL] [Abstract] [Full Text] [Related]
5. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
6. Prevalence and spectrum of germline brca1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health.
De Matteis E; Tumolo MR; Tarantino P; Ciccarese M; Grassi T; Bagordo F; De Giorgio MR; Rizzo E; Ronzino G
Oncotarget; 2024 Feb; 15():134-141. PubMed ID: 38386807
[TBL] [Abstract] [Full Text] [Related]
7. Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
Kim JH; Kim SI; Park EY; Kim ET; Kim H; Kim S; Park SY; Lim MC
Gynecol Oncol; 2024 Feb; 181():33-39. PubMed ID: 38104527
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
[TBL] [Abstract] [Full Text] [Related]
9. Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma.
Xu Y; Spear S; Ma Y; Lorentzen MP; Gruet M; McKinney F; Xu Y; Wickremesinghe C; Shepherd MR; McNeish I; Keun HC; Nijhuis A
Cell Rep; 2023 Oct; 42(10):113307. PubMed ID: 37858464
[TBL] [Abstract] [Full Text] [Related]
10. A predictive and prognostic model for surgical outcome and prognosis in ovarian cancer computed by clinico-pathological and serological parameters (CA125, HE4, mesothelin).
Klotz DM; Link T; Wimberger P; Kuhlmann JD
Clin Chem Lab Med; 2024 Feb; 62(3):530-539. PubMed ID: 37816681
[TBL] [Abstract] [Full Text] [Related]
11. Prophylactic Salpingo-Oophorectomy and Survival After brca1/2 Breast cancer Resection.
Martelli G; Barretta F; Vernieri C; Folli S; Pruneri G; Segattini S; Trapani A; Carolla C; Spatti G; Miceli R; Ferraris C
JAMA Surg; 2023 Dec; 158(12):1275-1284. PubMed ID: 37792368
[TBL] [Abstract] [Full Text] [Related]
12. The Tumor Suppressor brca1/2, cancer Susceptibility and Genome Instability in Gynecological and Mammary cancers.
Oubaddou Y; Ben Ali F; Oubaqui FE; Qmichou Z; Bakri Y; Ameziane El Hassani R
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3139-3153. PubMed ID: 37774066
[TBL] [Abstract] [Full Text] [Related]
13. High-grade serous ovarian carcinoma, the "Achiles' hill" for clinicians and molecular biologists: a molecular insight.
Bhattacharya R; Ghosh A; Mukhopadhyay S
Mol Biol Rep; 2023 Nov; 50(11):9511-9519. PubMed ID: 37737967
[TBL] [Abstract] [Full Text] [Related]
14. Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability.
Nelson L; Barnes BM; Tighe A; Littler S; Coulson-Gilmer C; Golder A; Desai S; Morgan RD; McGrail JC; Taylor SS
Chromosome Res; 2023 Aug; 31(3):21. PubMed ID: 37592171
[TBL] [Abstract] [Full Text] [Related]
15. [ovarian cancer: molecular pathology and molecularly targeted therapy].
Reis H; Völkl L; Demes M; Moinfar F; Wild PJ
Pathologie (Heidelb); 2023 Sep; 44(5):320-328. PubMed ID: 37584749
[TBL] [Abstract] [Full Text] [Related]
16. Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature.
Ishimoto H; Sakamoto N; Kido T; Ozasa M; Tsutsui S; Mori M; Setoguchi D; Takemoto S; Obase Y; Ishimatsu Y; Tomonaga C; Matsumoto K; Morisaki S; Miura K; Mukae H
BMC Pulm Med; 2023 Aug; 23(1):289. PubMed ID: 37553592
[TBL] [Abstract] [Full Text] [Related]
17. Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: association with treatment outcomes.
Alizzi Z; Saravi S; Khalique S; McDonald T; Karteris E; Hall M
Int J Gynecol Cancer; 2023 Sep; 33(9):1427-1433. PubMed ID: 37541687
[TBL] [Abstract] [Full Text] [Related]
18. Pathological findings and long-term prognosis in Korean brca1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Kang OJ; Lee SW; Kim JH; Park JY; Suh DS; Kim DY; Kim JH; Kim YM; Kim YT
Int J Gynecol Cancer; 2023 Nov; 33(11):1743-1749. PubMed ID: 37541685
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic value of ALK overexpression and molecular abnormalities in high-grade serous ovarian carcinoma.
Gorczyński A; Miszewski K; Gager Y; Koch S; Pötschke J; Ugrinovski D; Gabert J; Pospieszyńska A; Wydra D; Duchnowska R; Szymanowski B; Cierniak S; Kruecken I; Neumann K; Mirkov K; Biernat W; Czapiewski P
Cancer Biomark; 2023; 38(1):17-26. PubMed ID: 37522200
[TBL] [Abstract] [Full Text] [Related]
20. The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous ovarian Carcinoma-A Study by the Spanish Group for ovarian cancer Research (GEICO).
Pizarro D; Romero I; Pérez-Mies B; Redondo A; Caniego-Casas T; Carretero-Barrio I; Cristóbal E; Gutiérrez-Pecharromán A; Santaballa A; D'Angelo E; Hardisson D; Vieites B; Matías-Guiu X; Estévez P; Guerra E; Prat J; Poveda A; López-Guerrero JA; Palacios J
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446361
[TBL] [Abstract] [Full Text] [Related]
[Next]
